Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 85

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Neoplasm+1

Not recruiting

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VERT-002
  • Sponsor:Pierre Fabre Medicament

HIV infection

Not recruiting

Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Cardiac amyloidosis

Not recruiting

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Fibromyalgia

Not recruiting

Study on Psilocybin's Effect on Pain in Fibromyalgia Patients

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Psilocybine
  • Sponsor:Universiteit Maastricht

Study of Amlenetug for Patients with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amlenetug
  • Sponsor:H. Lundbeck A/S

Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vormatrigine
  • Sponsor:Praxis Precision Medicines Inc.

Malignant melanoma

Not recruiting

Study on Stopping Nivolumab or Pembrolizumab in Advanced Melanoma Patients After Achieving a Response

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Obesity

Not recruiting

Study to Evaluate the Effectiveness of Survodutide in Reducing Liver Fat and Weight in Patients with Obesity or Overweight and Non-Alcoholic Steatohepatitis (NASH)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

HIV infection

Not recruiting

Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Axicabtagene Ciloleucel
  • Sponsor:Universitaet Muenster

Uveitis+1

Not recruiting

Study on the Effects of Brepocitinib and Prednisone for Adults with Active Non-Infectious Uveitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Priovant Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.